Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation.

Unveiling the Hidden Inflammation: The Role of Pranlukast in Stable Asthma

Asthma, a chronic respiratory disease, is characterized by airway inflammation. Even in controlled asthmatics treated with inhaled corticosteroids, residual inflammation can persist. This study investigates the potential of pranlukast, an oral leukotriene receptor antagonist, as an add-on therapy for stable asthma. The study explores the additive effects of pranlukast in reducing peripheral airway inflammation and improving asthma control.

Pranlukast: A Potential Ally in the Fight Against Asthma Inflammation

The study suggests that pranlukast may have beneficial effects in improving asthma control by reducing residual airway inflammation. The findings highlight the potential of pranlukast as an add-on therapy for stable asthma, particularly in cases where inhaled corticosteroids alone are not sufficient to adequately manage inflammation and control symptoms.

Managing Asthma: A Multifaceted Approach

The study emphasizes the importance of a multifaceted approach to managing asthma. It highlights the need to address both the inflammatory component and the underlying airway hyperresponsiveness. The study suggests that a combination of inhaled corticosteroids and oral leukotriene receptor antagonists like pranlukast may be beneficial for optimizing asthma control and improving patient quality of life.

Dr.Camel's Conclusion

This study provides valuable insights into the role of pranlukast in managing stable asthma. It suggests that pranlukast may play a significant role in reducing residual airway inflammation and improving asthma control. The study encourages further research to explore the optimal use of pranlukast as an add-on therapy for stable asthma.